Landsberg Bennett & Dubbaneh’s Regeneron Pharmaceuticals REGN Stock Holding History

Landsberg Bennett & Dubbaneh’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$768K	Sell	1,346 -39	-3%	-$24.2K	0.1%	143
2021 Q2	$756K	Buy	1,385 +66	+5%	+$33.4K	0.1%	145
2021 Q1	$626K	Buy	1,319 +311	+31%	+$151K	0.09%	153
2020 Q4	$487K	Buy	+1,008	New	+$544K	0.07%	159
2019 Q2	–	Sell	-815	Closed	-$332K	–	230
2019 Q1	$332K	Buy	815 +97	+14%	+$39.9K	0.08%	179
2018 Q4	$268K	Buy	+718	New	+$263K	0.1%	166

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Landsberg Bennett & Dubbaneh's REGN Position: Q3 2021 in Review

Landsberg Bennett & Dubbaneh reduced its Regeneron Pharmaceuticals (REGN) stake by 2.8% in Q3 2021, selling an estimated $24.2K and leaving 1,346 shares worth $768K. The position accounts for 0.1% of the portfolio, ranked #143.

Landsberg Bennett & Dubbaneh first reported a position in REGN in Q4 2018 and has held it in 6 quarters since. 1,018 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

Landsberg Bennett & Dubbaneh held 1,346 shares of Regeneron Pharmaceuticals worth $768K as of Q3 2021.
Landsberg Bennett & Dubbaneh sold 39 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $24.2K.
Regeneron Pharmaceuticals made up 0.1% of Landsberg Bennett & Dubbaneh's portfolio in Q3 2021, its #143 holding.
Landsberg Bennett & Dubbaneh first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 6 quarters since.
1,018 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Landsberg Bennett & Dubbaneh's 13F filing for Q3 2021, filed 29 Oct 2021.